13.0% CAGR growth by 2023 in Histology and Cytology Market | Major Vendors - ABBOTT, BECTON DICKINSON AND COMPANY, DANAHER, F. HOFFMANN-LA ROCHE LTD, HOLOGIC, INC., MERCK KGAA, PERKINELMER, INC., SYSMEX CORPORATION, amongst others.

Asia-Pacific to Register the Fastest Growth

North America is expected to dominate the market with a large number of clinical research laboratories and academic institutes with better regulatory framework in the countries of this region. Asia-Pacific is expected to dominate with the fastest growth rate in the forecast period. The healthy CAGR is expected due to the surge in the scientific researches in the South Asian countries.

Detailed Sample Copy of Updated Analysis @ https://marketprognosis.com/sample-request/16836
Note: “If this link doesn’t work in Internet Explorer, kindly try pasting it in other browsers.”

According to the 2012 report of the World Health Organization (WHO), there were 14 million new cases of cancers, which were expected to rise by about 70% over the next two decades. The growing prevalence of cancer patients has a direct impact on increased demand for the histology and cytology market. Other driving factors include increasing standardization of pathological laboratories, technological advancement in the diagnostics and molecular techniques, and favorable reimbursement for cancer screening and laboratory tests. Histopathological and Cytopathological tests are surrounded by safety and diagnostic accuracy issues.

Request Discount on this report @ https://marketprognosis.com/discount-request/16836
Note: “If this link doesn’t work in Internet Explorer, kindly try pasting it in other browsers.”

Market Segments:
Histology and cytology market is segmented by:
1. Type of Examination: Histology, Cytology
2. Test Type: Microscopy-based Tests, Molecular Genetics Tests, Flow Cytometry
3. End User: Hospitals/Clinics, Biopharmaceutical Companies, Academia, Others
4. Geography: North America, South America, Europe, Asia Pacific, Middle East & Africa

Key Developments in the Market
• February 2018 u2013 BD received premarket approval from the US FDA for the BD Onclarity HPV assay, which can detect 14 types of high-risk human papillomavirus (HPV) from the specimens collected for cervical cancer screening

Enquiry before Buying @ https://marketprognosis.com/enquiry/16836
Note: “If this link doesn’t work in Internet Explorer, kindly try pasting it in other browsers.”

About Market Prognosis
We at Market Prognosis believe in giving a crystal clear view of market dynamics for achieving success in today's complex and competitive marketplace through our quantitative & qualitative research methods.
We help our clients identify the best market insights and analysis required for their business thus enabling them to take strategic and intelligent decision.
We believe in delivering actionable insights for your business growth and success.

Contact us:
ProgMark Pvt Ltd,
Thane - 421501
India.
Contact No: +1 973 241 5193
Email: sales@marketprognosis.com

This release was published on openPR.